Wellington Management Group LLP Purchases 577,848 Shares of Sarepta Therapeutics, Inc. $SRPT

Key Points

• Wellington Management Group LLP increased its stake in Sarepta Therapeutics by 27.9% during the first quarter, owning approximately 2.69% of the company valued at about $168.91 million.
• Analysts have given Sarepta Therapeutics a consensus rating of "Hold" with a price target of $43.50, with a range of ratings from "Buy" to "Sell" among multiple research firms.
• Sarepta Therapeutics reported a significant revenue increase of 68.4% year-over-year, with quarterly revenue reaching $611.09 million and an EPS of $2.02, exceeding consensus estimates.

Wellington Management Group LLP raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 27.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,646,619 shares of the biotechnology company's stock after acquiring an additional 577,848 shares during the quarter. Wellington Management Group LLP owned about 2.69% of Sarepta Therapeutics worth $168,907,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at about $30,000. Center for Financial Planning Inc. acquired a new position in Sarepta Therapeutics in the first quarter valued at approximately $31,000. Pandora Wealth Inc. acquired a new position in Sarepta Therapeutics in the first quarter valued at approximately $45,000. Brooklyn Investment Group boosted its holdings in shares of Sarepta Therapeutics by 450.4% during the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company's stock worth $46,000 after buying an additional 590 shares in the last quarter. Finally, UMB Bank n.a. grew its position in shares of Sarepta Therapeutics by 53.0% during the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock worth $51,000 after buying an additional 276 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SRPT shares. Piper Sandler boosted their target price on shares of Sarepta Therapeutics to $15.00 and gave the company a "neutral" rating in a research report on Tuesday, July 29th. Leerink Partnrs lowered shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Baird R W cut shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 18th. Royal Bank Of Canada decreased their target price on Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a research report on Thursday, July 17th. Finally, William Blair reaffirmed an "outperform" rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 29th. Eight research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $43.50.

Sarepta Therapeutics Stock Up 0.8%

NASDAQ SRPT traded up $0.16 during trading hours on Friday, hitting $20.22. The company's stock had a trading volume of 9,517,905 shares, compared to its average volume of 16,045,195. The company has a market capitalization of $1.98 billion, a PE ratio of -23.24 and a beta of 0.46. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $143.49. The company's 50-day simple moving average is $17.99 and its two-hundred day simple moving average is $50.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. During the same period in the previous year, the company posted $0.07 EPS. The company's revenue for the quarter was up 68.4% on a year-over-year basis. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.